Leadership across the drug development lifecycle: why one hiring approach doesn't fit all

Stage-mismatched leadership is one of the most expensive mistakes in biopharma, and one of the most avoidable.

A brilliant CMO from a top pharma company joins a Series A biotech. On paper, it’s a great hire. In practice, six months later, the team is frustrated, the board is nervous and the CMO is wondering why nothing works the way it used to. Nobody made a bad decision — they just made the wrong one for the stage.

Drug development is not one environment. It’s five distinct ones, each demanding a completely different kind of leader, and organisations that treat it as one continuous hiring brief are the ones that cycle through senior talent every two years wondering what went wrong.

The execution load in biotech compounds at every stage — science, capital, regulators, patients and organisational capability all bearing down simultaneously. The leader who can absorb that pressure at Phase 1 is rarely the same person who can absorb it at Phase 3, and getting that wrong doesn’t just cost money. It costs time. In drug development, time is the one thing that can’t be bought back.

Phase one: discovery and early research

At discovery stage, leadership is fundamentally scientific. The role demands someone who can work in genuine intellectual partnership with the research function while beginning to build the organisational scaffolding that later stages will depend on.

The trap is hiring someone impressive from large pharma R&D. They’re credentialled, experienced and used to managing large teams, but everything that made them effective in that environment — defined governance, structured processes, institutional resources — doesn’t exist yet. What the role actually requires is someone energised by building from nothing, comfortable operating before the data is clean and capable of making consequential calls under genuine uncertainty. Deep scientific credibility combined with a founder’s tolerance for ambiguity is a rare profile, but it’s the right one.

Phase two: IND and early clinical development

The moment an asset enters the clinic, the demands on leadership shift considerably. Regulatory affairs stops being administrative and becomes strategic. Clinical operations needs to scale at pace. Cross-functional coordination across medical, biostatistics, regulatory and manufacturing becomes the daily reality, and the FDA or EMA relationship moves from background consideration to active management.

Leaders who thrive at this stage combine scientific credibility with genuine systems thinking. They understand the regulatory pathway in granular detail and make IND-stage decisions with NDA strategy already in mind. The common mistake is appointing someone with strong clinical operations experience but shallow regulatory depth, or the reverse — both are expensive errors, and the sweet spot between them is rarer than most organisations assume, which is precisely why candidate assessment here needs to be most rigorous.

Phase three: late-stage development and pivotal trials

Phase 3 operates under a different kind of pressure entirely. The trials running now will define the company’s future, investors are watching every timeline update and the board is focused on readout dates. There is no room for indecision and no tolerance for ambiguity in execution.

Leaders at this stage need to combine execution focus with the ability to hold strategic context simultaneously. Genuine regulatory credibility is non-negotiable: experience with Advisory Committee meetings, FDA correspondence on labelling and building the pre-BLA relationship with the agency are specialist capabilities that, in a late-stage search, often represent the single most important differentiating factor between candidates.

What fails most often here is the early-stage leader who built something remarkable but isn’t temperamentally suited to the execution intensity of a pivotal programme. These are talented, committed people who are simply not the right fit for this particular chapter of the organisation’s development. Identifying that clearly and early is one of the harder parts of an executive search, and also one of the most important.

Phase four: regulatory submission and pre-launch

This phase is chronically underestimated, and that underestimation is itself a risk.

Most organisations treat the period between a pivotal readout and regulatory approval as a waiting room, but it isn’t. It’s one of the most operationally complex periods in the entire lifecycle. Submissions involve hundreds of documents and dozens of stakeholders, the regulatory relationship is at its most critical and commercial preparation needs to be accelerating simultaneously rather than waiting for a green light that hasn’t arrived yet.

Pre-launch commercial leaders need to be builders first. The role requires designing the go-to-market model, recruiting the field organisation and building payer and market access infrastructure, often before the final label is known. Those who struggle in this environment are typically those who have only ever inherited established commercial operations. Those who thrive have launched before with imperfect information and demonstrated the ability to adapt as the picture clarifies.

Phase five: post-launch and growth

Post-approval, the nature of the organisation has fundamentally changed. Revenue is real, and the board is asking different questions — market penetration, payer dynamics, lifecycle management and programme timelines are no longer the primary currency of progress.

This is where talent from established pharma can genuinely add value, provided the search is designed to assess whether candidates can operate effectively in an environment that still carries biotech pace and urgency. The best commercial leaders at this stage bring large pharma discipline and rigour without losing the energy and adaptability that got the company to launch in the first place.

The framework that makes sense of all of this

Martin Stenfeldt’s eight archetypes of life science entrepreneurs, from his book Scaling Life Sciences, offers a valuable shared language for understanding why stage-mismatched hiring happens and how to prevent it.

The Engineer builds with precision but may miss the market. The Marketeer drives momentum but rushes past critical detail. The Clinician brings patient urgency but resists process. The Scientist pushes hard on innovation but risks becoming anchored in the data. The Caring Activist leads with conviction but may lack the operational depth the stage requires. The Anarchist moves fast and breaks rules, sometimes the ones that matter most. The Corporate Suit brings structure but can struggle to adapt when the environment demands flexibility. The Serial Entrepreneur draws on all of these qualities, shaped by the hard lessons of previous ventures.

Each archetype has a stage where they thrive and a stage where they don’t. Recognising which one is in front of you, and whether their instincts genuinely match the organisation’s current inflection point, is what separates a strong hire from an expensive lesson. The full framework is available at scalinglifesciences.com.

How BioX makes it precise

Knowing that each phase demands a different kind of leader is one thing. Finding the right one with genuine confidence is another.

Talent Science™ runs a structured diagnostic before any search begins, producing a precision report that maps the organisation’s current stage, culture and leadership gaps into a clear and actionable profile. This goes beyond functional requirements to identify the specific personality, archetype and behavioural characteristics that will succeed at this moment in the organisation’s development, not in the role that existed six months prior.

BioX builds the search from that report, assessing every candidate against it so that the shortlist reflects genuine fit for the stage the organisation is actually at, rather than the one it has just come from.

The right leader, identified at the right moment, with the rigour to prove it. To discuss what the right leadership profile looks like for a current stage, contact the BioX team.